ActinomycinX2 (Actinomycin V) is a compound synthesized by various species of Streptomyces. It displays potent inhibition against methicillin-resistant Staphylococcus aureus (MRSA), with a minimum inhibitory concentration (MIC) of 0.25 μg mL. ActinomycinX2 possesses potential applications in the treatment of both cancer and bacterial infections.